BRKR vs TMO vs QGEN Stock Comparison

Bruker, Thermo Fisher Scientific and Qiagen Prices as of Nov 13, 2026 Peers: Industry group
BRKR Bruker Corp
$61.59 +10.8% 1M +47.4% 1Y
Market cap
$9.16B
P/E
–
Revenue (TTM)
$3.51B
Div. yield
0.00%
Life Sciences Tools Healthcare
2 wins
QGEN Qiagen N.V.
$49.90 +9.6% 1M +6.2% 1Y
Market cap
$10.82B
P/E
28.1x
Revenue (TTM)
$2.12B
Div. yield
–
Life Sciences Tools Healthcare
5 wins

Head to Head

12 decided of 12

Thermo Fisher Scientific leads on 5 of the 12 questions below (Thermo Fisher Scientific 5, Qiagen 5, Bruker 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionBRKRTMOQGENLeader
Larger companyMarket capitalisation $9.16B $256.19B $10.82B TMO
Cheaper on earningsLower P/E, profitable companies only -54.8x 36.2x 28.1x QGEN
Cheaper on forward earningsLower price / next fiscal year consensus EPS 28.0x 27.0x 21.2x QGEN
Faster revenue growthRevenue growth, trailing twelve months +2.2% +8.3% +2.2% TMO
More profitableNet margin, trailing twelve months -4.8% 14.9% 18.2% QGEN
Better return on capitalReturn on invested capital -1.7% 8.0% 7.4% TMO
Less leveragedLower net debt / EBITDA 10.0x 3.1x 1.2x QGEN
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% BRKR
Better 1-year returnPrice return, last 12 months +47.4% +20.7% +6.2% BRKR
Better 5-year returnAnnualised price return, 5 years -5.7%/yr +2.0%/yr -3.6%/yr TMO
Less volatileAnnualised volatility, 1 year 62.4% 30.7% 35.2% TMO
Higher overall scoreMean of the five percentile scores vs peers 48/100 60/100 69/100 QGEN

Percentile Scorecard

BRKRTMOQGEN

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisBRKRTMOQGEN
Valuation 69 #77 of 243 62 #94 of 243 74 #63 of 243
Growth 18 #187 of 228 41 #136 of 228 25 #171 of 228
Profitability 63 #82 of 222 82 #40 of 222 93 #16 of 222
Financial Health 19 #200 of 248 31 #172 of 248 60 #100 of 248
Shareholder Returns 69 #50 of 158 82 #29 of 158 94 #11 of 158
Overall 48 60 69
  • BRKR ranked among 252 companies in Medical Devices and Diagnostics
  • TMO ranked among 252 companies in Medical Devices and Diagnostics
  • QGEN ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodBRKRTMOQGENSPY
1 month +10.8%+4.0%+9.6% -2.0%
3 months +6.7%+19.1%+16.2% -2.8%
6 months +43.6%+59.7%+51.3% +2.0%
Year to date +30.7%+20.8%+5.4% +10.6%
1 year +47.4%+20.7%+6.2% +12.2%
3 years -0.1%+52.5%+13.0% +68.1%
3 years, per year 0.0%+15.1%+4.2% +18.9%
5 years -25.4%+10.2%-16.9% +61.4%
5 years, per year -5.7%+2.0%-3.6% +10.1%
10 years +169.3%+362.9%+56.5% +248.5%
10 years, per year +10.4%+16.6%+4.6% +13.3%

Risk

MeasureBRKRTMOQGENSPY
Volatility, 1Y 62.4%30.7%35.2% 13.6%
Downside volatility, 1Y 59.9%29.2%29.7% 13.9%
Beta vs S&P 500, 1Y 1.750.710.38 1.00
Return / volatility, 1Y 0.760.670.18 0.90
Max drawdown, 5Y -68.9%-41.5%-48.2% -25.4%
From 52-week high -7.4%-3.0%-10.3% -3.2%
52-week high $66.54$721.63$55.66 $779.14
52-week low $32.76$438.34$32.63 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleBRKRTMOQGEN
P/E now vs peer median -56.1xmedian 26.5x 36.6xmedian 26.5x 28.2xmedian 26.5x
P/S now vs peer median 2.7xmedian 2.7x 5.5xmedian 2.7x 5.1xmedian 2.7x
EV/EBITDA now vs peer median 69.3xmedian 18.4x 25.5xmedian 18.4x 17.7xmedian 18.4x
P/FCF now vs peer median 38.4xmedian 25.4x 34.2xmedian 25.4x 11.2xmedian 25.4x
P/B now vs peer median 4.1xmedian 2.5x 4.7xmedian 2.5x 3.1xmedian 2.5x
PEG now vs peer median 1.57median 0.98 4.84median 0.98 11.74median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsBRKRTMOQGEN
Revenue $3.51B $47.35B $2.12B
Gross profit $1.67B $19.45B $1.33B
Operating income -$69.80M $8.47B $448.74M
Net income -$115.70M $7.09B $384.93M
Free cash flow $244.70M $7.60B $964.47M
R&D $387.20M $1.40B $199.87M
EPS (diluted) $-1.10 $19.06 $1.76
Cash & equivalents $119.70M $5.46B $805.13M
Total debt $1.71B $41.37B $1.64B
Shares (diluted) 152.50M 371.00M 218.88M
Enterprise value $8.43B $232.71B $7.45B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricBRKRTMOQGEN
P/E -56.1x 36.6x 28.2x
P/FCF 38.4x 34.2x 11.2x
P/Operating cash flow 27.5x 27.8x 17.0x
P/S 2.7x 5.5x 5.1x
P/B 4.1x 4.7x 3.1x
P/Tangible book 4.2x 7.1x 3.4x
EV/EBITDA 69.3x 25.5x 17.7x
EV/EBIT -157.6x 34.8x 25.9x
EV/Revenue 3.1x 6.2x 5.5x
EV/FCF 45.0x 38.8x 12.1x
EV/Operating cash flow 32.2x 31.6x 18.3x
PEG (3Y EPS CAGR) 1.57 4.84 11.74

Growth

14 metrics
MetricBRKRTMOQGEN
Revenue growth (1Y) 2.2% 8.3% 2.2%
Revenue CAGR (3Y) 7.6% 2.9% 2.7%
Gross profit growth (1Y) 3.2% 7.8% 1.7%
Gross profit CAGR (3Y) 4.9% 4.0% 2.5%
Operating income growth (1Y) -209.1% 12.8% -7.6%
Operating income CAGR (3Y) -29.1% 7.2% 3.6%
Net income growth (1Y) -390.3% 7.9% -2.8%
Net income CAGR (3Y) -33.1% 6.2% 5.0%
EPS growth (1Y) -602.7% 9.7% -7.3%
EPS CAGR (3Y) -35.8% 7.6% 2.4%
Operating cash flow growth (1Y) 262.5% 21.9% -3.4%
Operating cash flow CAGR (3Y) 2.6% 4.5% 13.7%
Free cash flow growth (1Y) 2,408% 24.3% 1.1%
Free cash flow CAGR (3Y) 5.9% 5.1% 13.5%

Profitability

14 metrics
MetricBRKRTMOQGEN
Gross margin 47.7% 41.1% 62.8%
EBITDA margin 4.5% 24.4% 31.0%
Operating margin -2.0% 17.9% 21.2%
Pretax margin -2.0% 16.7% 21.7%
Net margin -4.8% 14.9% 18.2%
FCF margin 7.0% 16.0% 45.6%
Operating cash flow margin 9.7% 19.7% 30.0%
Return on equity -4.9% 13.2% 11.3%
Return on assets -2.0% 6.2% 6.5%
Return on invested capital -1.7% 8.0% 7.4%
Return on capital employed -1.5% 8.5% 8.5%
Asset turnover 0.6x 0.4x 0.4x
Cash conversion (OCF / net income) -3.0x 1.3x 1.6x
Stock comp / revenue – 0.7% 2.0%

Financial Health

11 metrics
MetricBRKRTMOQGEN
Debt / assets 29.4% 36.2% 27.6%
Debt / equity 0.7x 0.8x 0.5x
Net debt / EBITDA 10.0x 3.1x 1.2x
Debt / FCF 7.0x 5.4x 1.7x
Liabilities / assets 60.4% 52.1% 41.5%
Equity / assets 39.6% 47.9% 58.5%
Interest coverage -1.2x 12.0x 10.8x
Current ratio 1.8x 1.8x 2.6x
Quick ratio 0.7x 1.2x 1.9x
Cash ratio 0.1x 0.4x 1.3x
Altman Z-score – 4.18 4.14

Shareholder Returns

7 metrics
MetricBRKRTMOQGEN
Dividend yield 0.3% 0.3% 5.3%
Net buyback yield – 1.6% 0.6%
Shareholder yield 0.3% 1.8% 5.9%
Payout ratio (earnings) -26.2% 9.5% –
Payout ratio (FCF) 12.4% 8.9% –
Dividend growth (1Y) 32.3% 8.0% –
Dividend CAGR (3Y) 0.9% 10.1% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusBRKRTMOQGEN
Forward P/E 28.0xFY2026 27.0xFY2026 21.2xFY2026
EPS, next fiscal year $2.20FY2026 $25.92FY2026 $2.35FY2026
EPS growth, next FY +20.2%FY2026 +13.3%FY2026 -1.3%FY2026
EPS growth, the year after +5.5% +2.2% +17.9%
Revenue, next fiscal year $3.76BFY2026 $50.12BFY2026 $2.25BFY2026
Revenue growth, next FY +9.4%FY2026 +12.5%FY2026 +7.8%FY2026
Revenue growth, the year after +2.7% -2.7% -2.8%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersBRKRTMOQGEN
Held by institutions 93.1% 90.2% 67.3%
Institutions holding 418 2,627 338
Change in shares held, QoQ +3.6% +0.8% +16.5%
Institutions buying 249 1,145 216
Institutions selling 122 1,145 86
Buyers to sellers 2.04 1.00 2.51

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

BRKRTMOQGEN
BRKR 1.00 0.62 0.38
TMO 0.62 1.00 0.44
QGEN 0.38 0.44 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, BRKR, TMO and QGEN?

Thermo Fisher Scientific (TMO) is the largest by market capitalisation: Bruker (BRKR) $9.16B, Thermo Fisher Scientific (TMO) $256.19B, Qiagen (QGEN) $10.82B.

Which stock is cheaper, BRKR, TMO and QGEN?

Qiagen (QGEN) trades on the lowest price-to-earnings ratio (Bruker (BRKR) -54.8x, Thermo Fisher Scientific (TMO) 36.2x, Qiagen (QGEN) 28.1x). On next year's consensus earnings, Qiagen (QGEN) is cheapest (Bruker (BRKR) 28.0x, Thermo Fisher Scientific (TMO) 27.0x, Qiagen (QGEN) 21.2x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Thermo Fisher Scientific (TMO) grew revenue fastest over the trailing twelve months: Bruker (BRKR) +2.2%, Thermo Fisher Scientific (TMO) +8.3%, Qiagen (QGEN) +2.2%.

Which company is more profitable?

Qiagen (QGEN) has the highest net margin (Bruker (BRKR) -4.8%, Thermo Fisher Scientific (TMO) 14.9%, Qiagen (QGEN) 18.2%). On return on invested capital, Thermo Fisher Scientific (TMO) leads (Bruker (BRKR) -1.7%, Thermo Fisher Scientific (TMO) 8.0%, Qiagen (QGEN) 7.4%).

Which stock has performed better?

Over the past year Bruker (BRKR) returned the most: Bruker (BRKR) +47.4%, Thermo Fisher Scientific (TMO) +20.7%, Qiagen (QGEN) +6.2%. Over five years, Thermo Fisher Scientific (TMO) compounded fastest (Bruker (BRKR) -5.7%/yr, Thermo Fisher Scientific (TMO) +2.0%/yr, Qiagen (QGEN) -3.6%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Bruker (BRKR) has the highest dividend yield: Bruker (BRKR) 0.00%, Thermo Fisher Scientific (TMO) 0.00%, Qiagen (QGEN) 0.00%. Qiagen (QGEN) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Thermo Fisher Scientific (TMO) has been the steadiest (Bruker (BRKR) 62.4%, Thermo Fisher Scientific (TMO) 30.7%, Qiagen (QGEN) 35.2%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, BRKR, TMO and QGEN?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Thermo Fisher Scientific (TMO) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.